BioSpace News Archive

Rite Aid Corporation announced that it has increased the offer price and extended the early tender premium for its previously announced cash tender offers to purchase up to $100 million aggregate principal amount of its outstanding 7.70% Senior Notes due 2027 and 6.875% Senior Notes due 2028

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2019 financial results on Tuesday, November 5, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 5:30 AM Pacific Time/8:30 AM Eastern Time.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that the company will file for an extension to file its 10K for the fiscal year ended July 31, 2019 with the SEC, and therefore the pay date for the 1:1 dividend has been extended 30 days to Friday November 29, 2019, with the Ex-Date of Monday December 2, 2019.

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization (CDMO), today announced the launch of its new CDMO brand, ANI Global Source.

CardioFocus, Inc. announced that the first patients in France have been treated in the University Public Hospital of Nancy with the HeartLight Endoscopic Ablation System as part of an exclusive distribution partnership with MicroPort® CRM France.

QSP and Pharmacometric Strategies Used to Aid Lifesaving Therapy for ARS

Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices

The Company will continue to expend its efforts to complete the following activities in 2020

Beth is a highly experienced financial executive and board member and we are fortunate to have her join our Board of Directors

Attaining growth capital to revolutionize the infertility insurance industry.